Long-term Outcomes of Patients Treated for Bladder Exstrophy by Questionnaires. (QUALEXSTRO)

September 6, 2023 updated by: Hospices Civils de Lyon

Evaluation of Long-term Outcomes on Urinary Continence, Fecal Continence, Sexuality and Quality of Life of Patients Treated for Bladder Exstrophy by Questionnaires.

The bladder exstrophy epispadias complex (BEEC) is a rare spectrum of congenital conditions due to abnormal development of the cloacal membrane. Of these conditions, bladder exstrophy (BE) represent a mild form and requires several complex surgical corrections to gain access to a urinary and fecal acceptable continence and a normal sexual function at adulthood. Despite the surgeries, patients may suffer, in the long term, from functional impairments (incontinence, sexuality disorders) which can impact severely their quality of life. However, only a few studies investigate long term issues of bladder exstrophy patients, with heterogenous population and small samples.

The department of pediatric surgery of the Hospices Civils of Lyon is an expert center in the management of patients born with bladder exstrophy. At adulthood, departments of adult urology continue the follow-up and treat residual complications. Thus, a large cohort of adults and adolescents' patients with bladder exstrophy is currently followed at our institution.

Therefore, the aim of this study is to evaluate urinary continence, fecal continence, sexuality and quality of life among a large cohort of patients treated for bladder exstrophy, using questionnaires.

All patients over 15 years old and treated for bladder exstrophy at our institution are included in the study. Exclusion's criteria are : patients treated for epispadias or cloacal exstrophy, patients initially treated of their bladder exstrophy abroad with no access to the surgical report, patients under a guardianship measure. All included patients are contacted by e-mail or phone to answer the questionnaire. The purpose of statistical analysis is to evaluate the average score in each field of investigation:

  • Mean ICIQ score for urinary continence
  • Mean FLQI score for fecal continence
  • Mean FSFI score for sexuality in women
  • Mean IIEF-5 score for sexuality in men
  • Mean SF-12 score for quality of life, in comparison of mean SF-12 score in general French population based on literature

Secondary objectives are to assess the impact of different surgical strategies used for bladder exstrophy reparation on urinary continence, fecal continence, sexuality and quality of life ; to describe the population from a sociological point of view (level of study, profession, marital status) and to describe the population reproductive status (pregnancy, delivery modalities, paternity and maternity status, use of medically assisted procreation).

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

42

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bron, France, 69500
        • Hôpital Femme Mère Enfant
      • Bron, France
        • Hôpital Femme Mère et enfant

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 65 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The population is selected on the database of the hospital. All patients over 15 years old and treated for bladder exstrophy or cloacal exstrophy at our institution are included in the study.

Description

Inclusion Criteria:

  • Patients born with bladder exstrophy or cloacal exstrophy
  • Aged 15 and over at time of enrolment
  • Treated at the Hospices Civils of Lyon

Exclusion Criteria:

  • patients treated for epispadias
  • patients initially treated of their bladder exstrophy abroad with no access to the surgical report
  • patients under a guardianship measure
  • deceased patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of average score of ICIQ score for urinary continence
Time Frame: At inclusion

The study is descriptive, and the purpose is to evaluate the average score in each field of investigation:

- Mean ICIQ score for urinary continence

At inclusion
Assessment of FLQI score for fecal continence
Time Frame: At inclusion
- Mean FLQI score for fecal continence
At inclusion
Assessment of FSFI score and IIEF-5 score for sexuality in women and men
Time Frame: At inclusion
  • Mean FSFI score for sexuality in women
  • Mean IIEF-5 score for sexuality in men
At inclusion
Assessment of SF-12 score for quality of life
Time Frame: At inclusion

- Mean SF-12 score for quality of life, in comparison of mean SF-12 score in general French population based on literature.

Data on the average SF-12 score for the French population are available in the Gandek et al study, which validated the French version of the score in 1998.

At inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 20, 2023

Primary Completion (Actual)

July 13, 2023

Study Completion (Actual)

July 13, 2023

Study Registration Dates

First Submitted

January 6, 2023

First Submitted That Met QC Criteria

January 18, 2023

First Posted (Actual)

January 19, 2023

Study Record Updates

Last Update Posted (Actual)

September 7, 2023

Last Update Submitted That Met QC Criteria

September 6, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bladder Exstrophy

Clinical Trials on Self or straight administered questionnaire

Subscribe